TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00556413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02163421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab injection, for subcutaneous use (vedolizumab SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab injection, for subcutaneous use (vedolizumab SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab injection, for subcutaneous use (vedolizumab SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab IV
Description: Vedolizumab injection, for intravenous use (vedolizumab IV)
Study: NCT04004013

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lifenol®
Description: Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day
Study: NCT01415492

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD2
Description: The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD2+
Description: The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
Study: NCT02578329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensively advised Mediterranean diet
Description: Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
Study: NCT01661062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography (CT) Scan
Description: Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
Study: NCT01696760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 325 mg twice a day
Study: NCT01222975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: orally disintegrating tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: orally disintegrating tablets
Study: NCT00987116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone - Azathioprine
Description: Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone - Azathioprine
Description: Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days.
Study: NCT03261947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931
Description: TAK-931 hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931
Description: TAK-931 hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931
Description: TAK-931 hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931
Description: TAK-931 hard gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931
Description: TAK-931 hard gelatin capsules
Study: NCT05938751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAm_YOUNG ADULTS program
Description: The TEAm_YOUNG ADULTS program is an intervention to develop self-determination in young adults with autism. It consists of 20 1.5h weekly sessions. The intervention is conducted by two facilitators with expertise in autism and self-determination promotion. Groups are formed by 4 to 6 participants. The program can be applied online or in person. The first five sessions address specific characteristics and support needs of people with autism. The next ten sessions are focused on the development of self-determination. The last five sessions are focused on working with others and the closure of the group. The individual goals of every participant are considered in the beginning of the group and a weekly follow-up of goals is conducted.
Study: NCT03857984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: blood sample before and after a single HD
Study: NCT01696760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: 40 mg once daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCD
Description: Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCD
Description: Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
Study: NCT00808314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT
Description: A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
Description: A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
Description: A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
Study: NCT02404116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: Participants will receive treatment which focus's on helping reduce excessive thinking about health,

Intervention type: OTHER
Group type: OTHER
Intervention: Wait List
Description: Individuals are on a waiting list
Study: NCT01477723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Oral Nutritional Supplement
Description: Experimental ONS orally Two 8 fl oz servings/day
Study: NCT01369979

Intervention type: PROCEDURE
Intervention: Liver vein catheter
Description: Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.

Intervention type: PROCEDURE
Intervention: Liver vein catheter
Description: Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
Study: NCT00778011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg IV
Study: NCT02168010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgecine
Description: Analgesic drug under test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: Analgesic drug as positive control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank tablet as placebo.
Study: NCT05024500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARDSNet table
Description: The setting of the lowest PEEP level and FiO2 match stated by the table to achieve a goal oxygenation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving Pressure
Description: The setting of the lowest PEEP level by the lowest correspondent driving pressure, which is defined by the difference of plateau pressure, after a modified alveolar recruitment maneuver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: The setting of the PEEP level above the intersection of the curves representing relative alveolar overdistention and collapse, after a modified alveolar recruitment maneuver.
Study: NCT00205426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrecor
Description: Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
Study: NCT02447133

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: OCT Machine used for diagnostic purposes
Study: NCT04087460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein based pneumococcal vaccine(Low dose)
Description: 0.2mL,Intramuscular other name:PBPV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Protein based pneumococcal vaccine placebo(Low dose)
Description: 0.2mL,Intramuscular other name:PBPV placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein based pneumococcal vaccine(Middle dose)
Description: 0.5mL,Intramuscular other name:PBPV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Protein based pneumococcal vaccine placebo(Middle dose)
Description: 0.5mL,Intramuscular other name:PBPV placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein based pneumococcal vaccine(High dose)
Description: 1.0mL,Intramuscular other name:PBPV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Protein based pneumococcal vaccine placebo(High dose)
Description: 1.0mL,Intramuscular other name:PBPV placebo
Study: NCT03632655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prostate biopsy
Description: Men will be randomized to receiving either TPM or TRUS targeted biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prostate biopsy
Description: Men will be randomized to receiving either TPM or TRUS targeted biopsy
Study: NCT03554356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoBalloon Focal Ablation System
Description: CryoBalloon Focal Ablation System
Study: NCT01787227

Intervention type: DEVICE
Intervention: xTAG RPP

Intervention type: DEVICE
Intervention: xTAG RPP
Study: NCT03657355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 will be administered as 50 mg tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 will be administered as 50 mg tablets for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: ACT-541468 will be administered as 50 mg tablets for oral use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-placebo will be used.
Study: NCT01140321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronate
Description: Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta.
Study: NCT02436278

Intervention type: OTHER
Intervention: 4MGS
Description: Usual walking speed measured over 4 metres
Study: NCT01637974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INTERCOAT administration
Description: Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
Study: NCT00814086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or intraperitoneally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intraperitoneally
Study: NCT02154555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridement
Description: post-operative debridement at 1 week follow-up visit
Study: NCT01045109

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 4,000 I.U. softgel daily orally for 48 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
Study: NCT01611987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MStep
Description: Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General guideline approach
Description: Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
Study: NCT03163888

Intervention type: PROCEDURE
Intervention: Navigation TKR
Description: Traditional over Conventional TKR
Study: NCT01986166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEHD7945A
Description: MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
Study: NCT02638285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Study: NCT03996993

Intervention type: DRUG
Intervention: Casodex, Axumin
Description: Patients will receive hormone therapy if Axumin positive area appears.

Intervention type: RADIATION
Intervention: Salvage Radiation, Axumin
Description: Patients will receive salvage radiation therapy if Axumin positive area appears.
Study: NCT00050505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live vaccinia virus vaccine
Description: Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
Study: NCT03464162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Meetings
Description: Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Network Meetings
Description: Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
Study: NCT04589221

Intervention type: BEHAVIORAL
Intervention: Ad libitum energy intake
Description: Investigate ad libitum energy intake according to degree of food processing and eating behaviour
Study: NCT04271189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin-Sitagliptin-Empaglifozin-Pioglitazone
Description: 1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Usual medical care to treat diabetes.
Study: NCT03349346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablet (s) or dispersible tablets for suspension administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablet (s) or dispersible tablets for suspension administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3 mg/m\^2 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3 mg/m\^2 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 635 mg/m\^2 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 635 mg/m\^2 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 administered intravenously